Uncontrolled fibrosis is a driving factor in several debilitating disease states. Progressive fibrosis leads to organ dysfunction and failure, and potentially death. In the U.S., many millions of Americans are afflicted with a fibrosis-related disease, which may affect organs including the kidney, liver, lungs, skin, and eye.

The underlying pathophysiology of fibrosis is complex and incompletely understood. As a result, there is a pressing need to identify novel targets that are critical to the fibrotic process. Key diseases characterized by uncontrolled fibrosis include diabetic nephropathy, idiopathic pulmonary fibrosis, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis (PBC), systemic sclerosis, and corneal fibrosis.

Our foundational programs are based on cutting edge research licensed from Hal Dietz, M.D. and his team at Johns Hopkins University. We are applying these meaningful insights to discover disease-modifying drugs that broadly modulate fibrotic disease, and may ultimately be of benefit to and change outcomes for millions of patients.

Blade’s focus is identifying targets that are critical to the fibrotic process and advancing them into drug discovery and development.

Blade Therapeutics MOA image